MX2022007304A - Uso de lemborexant para tratamiento del insomnio. - Google Patents

Uso de lemborexant para tratamiento del insomnio.

Info

Publication number
MX2022007304A
MX2022007304A MX2022007304A MX2022007304A MX2022007304A MX 2022007304 A MX2022007304 A MX 2022007304A MX 2022007304 A MX2022007304 A MX 2022007304A MX 2022007304 A MX2022007304 A MX 2022007304A MX 2022007304 A MX2022007304 A MX 2022007304A
Authority
MX
Mexico
Prior art keywords
lemborexant
pharmaceutically acceptable
acceptable salt
treating insomnia
patient
Prior art date
Application number
MX2022007304A
Other languages
English (en)
Spanish (es)
Inventor
Margaret Moline
Andrew Satlin
Ishani Landry
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2022007304A publication Critical patent/MX2022007304A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2022007304A 2019-12-20 2020-12-18 Uso de lemborexant para tratamiento del insomnio. MX2022007304A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951638P 2019-12-20 2019-12-20
PCT/US2020/065891 WO2021127359A1 (en) 2019-12-20 2020-12-18 Use of lemborexant for treating insomnia

Publications (1)

Publication Number Publication Date
MX2022007304A true MX2022007304A (es) 2022-08-22

Family

ID=74191874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007304A MX2022007304A (es) 2019-12-20 2020-12-18 Uso de lemborexant para tratamiento del insomnio.

Country Status (11)

Country Link
US (1) US20230051268A1 (cg-RX-API-DMAC7.html)
EP (1) EP4076463A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023508011A (cg-RX-API-DMAC7.html)
KR (1) KR20220119065A (cg-RX-API-DMAC7.html)
CN (1) CN115003305A (cg-RX-API-DMAC7.html)
AU (1) AU2020408557A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012246A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165481A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022007304A (cg-RX-API-DMAC7.html)
TW (1) TW202137986A (cg-RX-API-DMAC7.html)
WO (1) WO2021127359A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260029363A (ko) * 2023-06-29 2026-03-04 얀센 파마슈티카 엔브이 셀토렉산트를 이용한 우울증 치료 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828751A4 (en) 1995-05-05 1999-01-20 Human Genome Sciences Inc HUMAN NEUROPEPTIDE RECEPTOR
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
RU2571414C2 (ru) 2010-09-22 2015-12-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Циклопропановые соединения
US9416109B2 (en) 2012-02-17 2016-08-16 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of orexin-2 receptor antagonists
JP6659681B2 (ja) * 2014-10-23 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症を治療するための組成物および方法
KR20230170136A (ko) * 2017-01-27 2023-12-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법

Also Published As

Publication number Publication date
BR112022012246A2 (pt) 2022-08-30
CA3165481A1 (en) 2021-06-24
US20230051268A1 (en) 2023-02-16
KR20220119065A (ko) 2022-08-26
EP4076463A1 (en) 2022-10-26
CN115003305A (zh) 2022-09-02
JP2023508011A (ja) 2023-02-28
WO2021127359A1 (en) 2021-06-24
AU2020408557A1 (en) 2022-08-11
TW202137986A (zh) 2021-10-16
JP2025160480A (ja) 2025-10-22

Similar Documents

Publication Publication Date Title
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
PH12019500025A1 (en) Cancer treatment combinations
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
ZA202000028B (en) Use of vibegron to treat overactive bladder
PH12019502334A1 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
ZA202204907B (en) Orally disintegrating pharmaceutical compositions of apixaban
PH12021550218A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
PH12019500516A1 (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
BR112022012246A2 (pt) Uso de lemborexant para tratar insônia
RU2016103099A (ru) Способ предотвращения и/или лечения хронической травматической энцефалопатии - i
HRP20230693T1 (hr) Uporaba inhibitora acetilkolinesteraze i idalopirdina za smanjenje padova kod pacijenata oboljelih od parkinsonove bolesti
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
MX2026000090A (es) Lemborexant para el tratamiento de problemas del sueño
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera
PH12019501607A1 (en) Tapentadol nasal composition
MX2022002038A (es) Composicion farmaceutica para el tratamiento del insomnio.
WO2016187595A3 (en) Oral pharmaceutical composition of methylergonovine
ZA202206042B (en) Treating behavioral and psychological symptoms in dementia patients
RU2018133603A (ru) Пероральная дозированная форма двух изомеров кломифена и способ ее использования для лечения вторичного гипогонадизма и минимизации побочных эффектов лекарственного препарата у мужчин
WO2016193456A3 (en) Opioid receptor antagonist for use in treating patients with severe constipation
RU2010113937A (ru) Производные 1-аминоалкилциклогексана для лечения и предупреждения потери слуха